BioLineRx (NASDAQ:BLRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report sent to investors on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock.

BioLineRx Stock Down 4.4 %

BLRX opened at $0.41 on Thursday. The company has a fifty day moving average of $0.56 and a two-hundred day moving average of $0.64. The stock has a market capitalization of $32.78 million, a price-to-earnings ratio of -0.91 and a beta of 1.46. BioLineRx has a fifty-two week low of $0.39 and a fifty-two week high of $1.93. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.49 and a current ratio of 1.61.

BioLineRx (NASDAQ:BLRX) last announced its earnings results on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The business had revenue of $5.39 million for the quarter, compared to analysts’ expectations of $3.93 million. On average, research analysts expect that BioLineRx will post -0.25 earnings per share for the current year.

Hedge Funds Weigh In On BioLineRx

An institutional investor recently bought a new position in BioLineRx stock. CVI Holdings LLC bought a new position in shares of BioLineRx Ltd. (NASDAQ:BLRX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 815,683 shares of the biotechnology company’s stock, valued at approximately $462,000. CVI Holdings LLC owned 1.02% of BioLineRx at the end of the most recent reporting period. 1.56% of the stock is owned by institutional investors.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.